Weight loss drugs such as Wegovy and Zepbound are clinically effective but not cost effective at their current prices, according to a study published in JAMA Health Forum. Tirzepatide and semaglutide, ...

Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News — ...

A new UCLA Health study found that taking an 8-strain probiotic daily may reduce the risk of pouchitis, a common inflammatory condition that occurs after colon removal surgery for ulcerative colitis, ...

Two popular medications used in the fight against obesity—semaglutide (Wegovy; Novo Nordisk) and tirzepatide (Zepbound; Eli Lilly)—are priced too high to be considered cost-effective by currently ...